Experience

Veranex
• United States
• Medical Equipment Manufacturing
• 300 - 400 Employee
• SVP, Commercial Strategy & Market Access

  • May 2022 - Present


University of California, San Francisco

• United States
• Higher Education
• 700 & Above Employee

• Deputy Director, Center for Translational & Policy Research in Precision Medicine

  • Jul 2021 - May 2022

  Lead research projects and bring together academic, government and industry leaders to explore how personalized/precision medicine can best be applied to improve health. Use approaches including observational studies, real world data studies, stakeholder engagement, economic evaluations, implementation science and coverage policy analyses to gather evidence about how precision medicine technologies are being integrated into clinical practice and health policy. Lead research projects and bring together academic, government and industry leaders to explore how personalized/precision medicine can best be applied to improve health. Use approaches including observational studies, real world data studies, stakeholder engagement, economic evaluations, implementation science and coverage policy analyses to gather evidence about how precision medicine technologies are being integrated into clinical practice and health policy.



Deverka Consulting

• United States
• Telecommunications

• Health Economics and Outcomes Research (HEOR) Consultant

  • Feb 2020 - May 2022

  Lead HEOR planning efforts for biotech companies and start-ups in the precision medicine space. Oversee development of cost-effectiveness models, RWE studies and patient-centered outcomes research to support value propositions for novel diagnostics and drugs. Conduct payer and other stakeholder research to characterize clinical and economic evidence requirements for informed decision-making. Advise clients on study protocol design, study conduct, analysis and peer-reviewed publications in support of HEOR objectives.



Geisinger National Precision Health

• Director, Value Evidence and Outcomes

  • Feb 2019 - Jan 2020

  Designed and led the strategy to build Geisinger National's health economics and outcomes research capabilities, focused on assessing the value of Precision Health within and across health plans and systems. Developed robust, real-world evidence to support economic value propositions and reimbursement of precision health technologies. Designed and led the strategy to build Geisinger National's health economics and outcomes research capabilities, focused on assessing the value of Precision Health within and across health plans and systems. Developed robust, real-world evidence to support economic value propositions and reimbursement of precision health technologies.



American Institutes for Research

• United States
• Research
• 700 & Above Employee

• Principal Researcher

  • Oct 2014 - Jan 2019

  Principal researcher in the Health Services Group at AIR where my grant-funded research focused on coverage issues related to genomic sequencing and policies to support genotype/phenotype data sharing. Also led business development teams and have won large federal contracts to support the adoption of evidence by learning healthcare systems, as well as projects funded by PCORI and RWJF in patient engagement and patient-centered measurement. Principal researcher in the Health Services Group at AIR where my grant-funded research focused on coverage issues related to genomic sequencing and policies to support genotype/phenotype data sharing. Also led business development teams and have won large federal contracts to support the adoption of evidence by learning healthcare systems, as well as projects funded by PCORI and RWJF in patient engagement and patient-centered measurement.



Center for Medical Technology Policy

• United States
• Public Policy
• 1 - 100 Employee

• Senior Research Director

  • Jun 2010 - Jun 2014

  My research portfolio emphasized projects focused on methods for patient and other stakeholder engagement in comparative effectiveness research. Working collaboratively, I have successfully obtained grants from PCORI, AHRQ and foundations to ensure patient involvement in research infrastructure development, research priority setting, study design and results implementation. I also worked extensively in the area of genomics and have obtained grants to explore the reimbursement challenges with next generation sequencing technologies and to develop methodological recommendations for designing studies to demonstrate the clinical utility of molecular diagnostics. Most of my work includes engaging stakeholders such as patients, payers, clinicians and policy-makers through the use of both qualitative and quantitative methods.



University of North Carolina at Chapel Hill

• Research
• 1 - 100 Employee

• Research Associate Professor

  • Jan 2008 - Jun 2010

  As a member of the pharmacy department faculty, I conducted policy research at the Institute for Pharmacogenomics and Individualized Therapy, a multi-disciplinary group that studies how personalized medicine will be translated into clinical practice. As a member of the pharmacy department faculty, I conducted policy research at the Institute for Pharmacogenomics and Individualized Therapy, a multi-disciplinary group that studies how personalized medicine will be translated into clinical practice.



Medco

• India
• Events Services
• 1 - 100 Employee

• VP, Scientific Affairs

  • 2000 - 2004

  I was responsible for building relationships with top-tier universities and key professional organizations that focus on evaluating the costs and quality of pharmaceutical therapy. I also developed white papers, client presentations and business strategy for Medco Health on scientific developments in personalized medicine and genomics.

• VP, Clinical Analysis and Outcomes Research

  • 1998 - 2000

  I was responsible for developing a top tier health services research group within a large pharmacy benefit management (PBM) company. The group focused on differentiating Medco Health by measuring the impact of PBM services on pharmacy and total healthcare costs as well as patient health outcomes, quality of life and satisfaction with pharmaceutical care. This group was responsible for the design and evaluation of health management programs targeting chronic diseases such as hypertension, hypercholesterolemia, diabetes, asthma and depression.



Janssen Research Foundation (JNJ)

• VP, Outcomes Research

  • 1994 - 1998

  Managed and developed a group of outcomes research professionals, including physicians, pharmacists, epidemiologists, economists, statisticians and programmers. Managed and developed a group of outcomes research professionals, including physicians, pharmacists, epidemiologists, economists, statisticians and programmers.



Abbott Laboratories

• Colombia
• Personal Care Product Manufacturing
• 200 - 300 Employee

• Director, Epidemiology and Outcomes Research

  • Jul 1990 - Dec 1993

  I started a pharmacoepidemiology function at Abbott that transitioned to become an outcomes research department. I was responsible for recruiting and managing the outcomes researchers and overseeing a pragmatic clinical trial as well as other prospective and retrospective studies. I started a pharmacoepidemiology function at Abbott that transitioned to become an outcomes research department. I was responsible for recruiting and managing the outcomes researchers and overseeing a pragmatic clinical trial as well as other prospective and retrospective studies.